Filter
259
Text search:
drug
manufacturing
Featured
Recommendations
24
New Publications
54
Language
Document type
No document type
107
Studies & Reports
59
Guidelines
50
Strategic & Response Plan
17
Manuals
13
Fact sheets
6
Situation Updates
3
Resource Platforms
2
Training Material
1
Brochures
1
Countries / Regions
Ghana
14
Global
13
Kenya
12
India
8
Ethiopia
7
Uganda
6
Zimbabwe
6
South Africa
6
Zambia
5
Tanzania
5
Botswana
5
Western and Central Europe
5
Nigeria
4
Malawi
4
South–East Asia Region
4
Africa
4
Philippines
3
Nepal
3
Eastern Europe
3
Sierra Leone
2
Senegal
2
Rwanda
2
Sudan
2
Latin America and the Carribbean
2
Congo, Democratic Republic of
1
Cameroon
1
Pakistan
1
Syria
1
Cambodia
1
Indonesia
1
Bangladesh
1
Mozambique
1
Ukraine
1
Lesotho
1
Asia
1
Tajikistan
1
Russia
1
Moldova
1
Uzbekistan
1
Vietnam
1
Turkmenistan
1
Maldives
1
Authors & Publishers
Publication Years
Category
Countries
100
Clinical Guidelines
17
Pharmacy & Technologies
14
Key Resources
10
Public Health
8
Women & Child Health
3
Capacity Building
2
Toolboxes
AMR
31
COVID-19
30
Pharmacy
28
HIV
18
TB
18
Mental Health
12
Planetary Health
10
Malaria
5
NTDs
4
NCDs
4
Ebola & Marburg
3
Conflict
3
Rapid Response
3
Specific Hazards
3
Global Health Education
3
Caregiver
3
Health Financing Toolbox
3
Natural Hazards
2
2.0 Rapid Response
2
Disability
1
Cholera
1
Polio
1
Refugee
1
Document No. : FDA/SMC/CTD/GL-CCT/2013/01
This fourth annual report monitors global progress towards the 2023 target for global elimination of industrially produced trans-fatty acids (TFA), highlighting achievements during the past year (October 2021 – September 2022). Countries are responding to the World Health Organization (WHO) call t
...
WHO Pharmacovigilance indicators: a practical manual for the assessment of pharmacovigilance systems
This manual provides a practical method for determining the pharmacovigilance indices. It is designed to be simple and can be understood by any worker in pharmacovigilance without formal training in monitoring and evaluation. Pharmacovigilance as a medical discipline is crucial in preventing medicin
...
PlosOne January 20, 2021
https://doi.org/10.1371/journal.pone.0241899
Antibiotic fixed dose combinations (FDCs) can have clinical advantages such as improving effectiveness and adherence to therapy. However, high use of potentially inappropriate FDCs has been reported, with implications for antim
...
5th edition.
Lessons from the STEP-TB Project.
Accessed November 2017.
Environmental pollution, protection, quality and sustainability
Reports of antimicrobial-resistant (AMR) microorganisms are increasing globally, threatening to render existing treatments ineffective against many infectious diseases. In Africa, AMR has already been documented to be a problem for human immunodeficiency virus (HIV) and the pathogens that cause mala
...
The Global Strategy for Tuberculosis Research and Innovation will support the efforts of governments and other stakeholders to accelerate TB research and innovation, and improve equitable access to the benefits of research.
Availabl in Arabic, Chinese, English, French, Spanish and Russian
This guide contains recommendations for health and safety practices and approaches to COVID-19 prevention, based on materials developed by many organisations.
Fact Book on WHO Level I and Level II monitoring indicators - To monitor the progress of efforts to improve the global medicines situation, WHO has developed a system of indicators that measure important aspects of a country’s pharmaceutical situation. Level 1 indicators measure the existence and
...
The review’s objectives are to review progress in TB control with emphasis on DOTS strategy implementation, summarize the experience, lessons learnt and methods of work and to make recommendations for international donors, technical agencies and the Ministry of Health.
• provide scientific information on the safety, efficacy, and quality control/ quality assurance of widely used medicinal plants, in order to facilitate their appropriate use in Member States;
• provide models to assist Member States in developing their own mono- graphs or formularies for these
...
